Antibody-drug conjugates (ADCs) represent a ground-breaking fusion of precision medicine and cancer treatment. These innovative therapies combine the targeting specificity of monoclonal antibodies with the potent cytotoxicity of chemotherapeutic drugs. The antibody component precisely homes in on cancer cells, while the attached drug payload delivers a highly targeted punch, minimizing damage to surrounding healthy tissues. This nuanced approach enhances the therapeutic index and reduces systemic side effects commonly associated with traditional chemotherapy. ADCs have shown remarkable efficacy in treating various cancers, offering new hope for patients with challenging malignancies.
As the landscape of cancer treatment evolves, antibody-drug conjugates stand out as a promising avenue, epitomizing the intersection of advanced science and compassionate care in the fight against cancer. As research continues to advance, the development of next-generation ADCs holds promise for even greater precision and effectiveness in the fight against cancer. The era of antibody-drug conjugates represents a significant leap forward in personalized cancer therapy, ushering in a new paradigm of treatment that maximizes efficacy while minimizing the impact on healthy tissues.
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Vladlen Slepak
University of Miami Miller School of Medicine, United States
Andreas M Papas
Antares Health Products, United States
Sergey Suchkov
The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian FederationSubmit your abstract Today
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Emerging formulation and delivery applications of Vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : The promise of nanotechnology in personalized & precision medicine: Drug discovery & development being partnered with nanotechnologies via the revolution at the nanoscale
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through design-inspired biotech- & biopharma-driven applications and upgraded business marketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad Autónoma de Baja California, Mexico
Title : Antibody-proteases as translational tools of the next-step generation to be applied for biopharmacy-related and precision medical practice
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia